期刊文献+

强心冲剂对充血性心力哀竭家兔模型心钠素、血管紧张素Ⅱ的影响 被引量:2

Influence of Qiangxin Chongji on Atrial Natriuretic Polypeptide and Angiotensin Ⅱ of Rabbit Model with Congestive Heart Failure
下载PDF
导出
摘要 目的:观察强心冲剂干预后充血性心力衰竭(CHF)家兔模型心钠素(ANP)、血管紧张素Ⅱ(AngⅡ)的变化,探讨强心冲剂对神经内分泌活性的影响。方法:将40只家兔随机分为4组,假手术组、模型组、地高辛组、强心冲剂组,每组10只。采用腹主动脉缩窄术建立家兔CHF模型,予强心冲剂和地高辛灌胃,检测并比较ANP、AngⅡ的活性。结果:CHF家兔模型ANP、AngⅡ活性显著升高,神经内分泌激素释放失衡,强心冲剂干预后,可以纠正其失衡状态,明显降低ANP、AngⅡ水平。结论:强心冲剂能显著纠正神经内分泌激素释放失衡状态,改善神经内分泌激素的激活,可以防止CHF的进一步恶化。 Objective:To probe the influence of Qiangxin Chongji (Infusion for strengthening the function of heart) on the activity of neuroendocrine of rabbit model with congestive heart failure (CHF) through observing the changes of atrial natriuretic polypeptide (ANP) and angiotensin Ⅱ (Ang Ⅱ). Methods:The 40 rabbits were randomized into 4 groups with 10 in each: false operation group, model group, digoxin group, Qiangxin Chongji group. The CHF models were made by abdominal aorta constriction. The gastric perfusion with Qiangxin Chongji and digoxin was applied. The activity of ANP and Ang Ⅱ was tested and compared. Results:The activity of ANP and Ang Ⅱ was clearly strengthened and the neuroendocrine was imbalanced. Intervention of Qiangxin Chongji could correct this imbalanced condition, lowering ANP and Ang Ⅱ obviously. Conclusion:Qiangxin Chongji can remarkably correct the imbalanced hormone release of neuroendocrine and improve the hormone activation to prevent the CHF deterioration.
出处 《世界中西医结合杂志》 2007年第11期631-632,645,共3页 World Journal of Integrated Traditional and Western Medicine
基金 天津市高等学校科技发展基金项目资助课题(990212)
关键词 充血性心力衰竭 心钠素 血管紧张素Ⅱ 强心冲剂 Congestive heart failure (CHF) Atrial natriuretic polypeptide (ANP) or cardionatin Angiotensin (Ang Ⅱ) Qiangxin Chongji (Infusion for strengthening the function of heart)
  • 相关文献

参考文献8

二级参考文献60

  • 1顾复生.充血性心力衰竭治疗进展[J].国外医学(内科学分册),1994,21(10):415-420. 被引量:42
  • 2都本洁.心力衰竭的治疗进展[J].临床荟萃,1994,9(22):1009-1012. 被引量:7
  • 3Maeda K,Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin - 6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol, 2000;36 (5):1581~1593
  • 4Cargill RI, Barr CS, Coutie WJ, et al. C-type natriuretic peptide levels in corpulmonale and in congestive heart failure. Thorax, 1994;49(12): 1247~1249
  • 5Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B - natriuretic as a rapid,point-of- care test for screening patients udnergoing echocardiography to determine left ventricular dysfunction. Am Heart J ,20011; 141 (3) :367~374
  • 6Kawai K, Hata K,Tokaoka H, et al. Plasma brain natriuretic peptide as a nove therapeutic indicator in idiopathic dilated cardiomyopathy during beta- blocker therapy:a potential of hormone- guided treatment. Am Heart J ,2001; 141 (6) :925 ~932
  • 7Francis GS. Pathophysiology of chronic heart failure[J]. Am J Med, 2001,110(Suppl 7A): 37S-46S.
  • 8Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress[J]. Circulation, 2000,102:IV-14.
  • 9Sabbah HN. Apoptotic cell death in heart failure[J]. Cardiovasc Res, 2000, 45:704-712.
  • 10Ungerer M, Bohm M, Elce JS, et al. Altered expression of β-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart[J]. Circulation,1993,87:454-463.

共引文献123

同被引文献37

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部